{
  "page_summary": "This page discusses the importance of cardiac safety assessments for breast cancer patients treated with certain therapeutics known to cause cardiotoxicity, listing typical agents and their associated cardiac risks. It then provides general guidance on data management for tumor identification, assessment, and disease response using SDTM domains (TU, TR, RS), briefly describing different CRF collection strategies and methods for linking tumor data across assessment periods but does not detail or define specific clinical endpoints.",
  "endpoint_candidates": []
}